Deciphera Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Deciphera Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q1 2024.
  • Deciphera Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $10.2M, a 18.7% decline year-over-year.
  • Deciphera Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $48.3M, a 3.84% decline year-over-year.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $50.6M, a 2.58% decline from 2022.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $51.9M, a 12.7% increase from 2021.
  • Deciphera Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $46.1M, a 24.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $48.3M $10.2M -$2.34M -18.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $50.6M $14.1M +$1.76M +14.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-07
Q3 2023 $48.8M $11.2M -$1.21M -9.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-30
Q2 2023 $50.1M $12.9M -$132K -1.02% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $50.2M $12.5M -$1.75M -12.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $51.9M $12.3M +$1.52M +14.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-07
Q3 2022 $50.4M $12.4M +$579K +4.91% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-30
Q2 2022 $49.8M $13M +$617K +4.99% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $49.2M $14.3M +$3.15M +28.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $46.1M $10.8M +$1.09M +11.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-07
Q3 2021 $45M $11.8M +$1.97M +20% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $43M $12.4M +$1.76M +16.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $41.3M $11.1M +$4.13M +59% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $37.1M $9.71M +$4.36M +81.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-07
Q3 2020 $32.8M $9.83M +$5.1M +108% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $27.7M $10.6M +$6.5M +158% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $21.2M $6.99M +$765K +12.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $20.4M $5.35M +$2.54M +90.6% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-08
Q3 2019 $17.9M $4.73M +$2.12M +80.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $15.8M $4.11M +$1.88M +84% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $13.9M $6.23M +$4.19M +206% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $9.69M $2.81M -$39K -1.37% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-09
Q3 2018 $9.73M $2.61M +$1.6M +158% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $8.13M $2.23M +$1.64M +276% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 $6.49M $2.04M +$1.62M +390% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $4.87M $2.84M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-09
Q3 2017 $1.01M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $594K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $416K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.